BPC-157 10mg Pen

Scientific Product Information

Product overview

BPC-157 10mg Pen | Futureproof Peptides is the product name supplied for this listing. BPC-157, also known as Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It has been investigated in preclinical scientific research involving peptide biology, cellular signalling and various biological processes.

The supplied product name identifies a 10mg pen presentation and Futureproof Peptides as the stated brand. However, the precise formulation, peptide concentration, pen-device specifications, excipients, manufacturer details and batch documentation have not been independently verified.

An important distinction should be made between the scientific compound and the particular commercial presentation. Published research about BPC-157 does not establish the composition, quality, safety or suitability of a specific pen product.

BPC-157 is an investigational compound and is not an MHRA-authorised medicine. This page therefore provides scientific and product-identification information rather than instructions or promotional claims relating to human use.

Understanding the BPC-157 pen presentation

The supplied product name identifies a pen format rather than a conventional research vial.

A pen is a delivery-device presentation, but its name alone does not establish how the device works, its compatibility, its contents or whether it has been validated for any particular application.

For accurate product identification, the following details require confirmation from Futureproof Peptides or the original manufacturer:

• Total peptide content.

• Whether 10mg represents the total pen contents.

• Peptide formulation and chemical form.

• Device manufacturer and model.

• Pen mechanism and specifications.

• Included components and packaging.

• Batch identification and analytical documentation.

• Manufacturer-provided storage and handling information.

These distinctions are important when reviewing product specifications and comparing scientific reference materials.

Why accurate BPC-157 product information matters

BPC-157 is frequently discussed in peptide research catalogues and scientific literature. However, a compound’s scientific history should not be confused with the verification of a particular commercial product.

Reliable identification requires attention to the peptide’s stated identity, quantity, formulation and supporting documentation.

For the Futureproof Peptides listing, the brand and product name are supplied by the product brief. Independent authentication of the brand, manufacturer and specific 10mg pen presentation has not been established.

A transparent product record should clearly distinguish confirmed information from specifications that still require supporting evidence.

Research information and scientific background

BPC-157 is a synthetic peptide consisting of 15 amino acids. It is commonly described in scientific literature as a peptide fragment associated with a protein found in gastric juice.

Scientific interest in BPC-157 has primarily involved preclinical investigations. These include laboratory studies and animal models examining biological signalling, cellular responses and various tissue-related processes.

A scientific review published in 2025, titled Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, discusses the available preclinical literature and highlights substantial limitations in the human evidence.

Read the publication through PubMed Central – BPC-157 systematic review.

A further review published in 2026 examines the pharmaceutical development challenges associated with BPC-157, including formulation characterisation, pharmacokinetics and the limitations of existing clinical evidence. BPC-157: Investigational Peptide Therapeutic – Scientific Review.

These publications are useful for understanding the research landscape. Experimental observations should not be presented as established human benefits or proof of clinical safety.

Current scientific evidence

Although BPC-157 has been investigated in numerous preclinical studies, the available human evidence remains very limited.

A systematic review published in 2026 evaluated the available human studies and identified substantial limitations in study quality, participant numbers and certainty of evidence. It concluded that BPC-157 should not be used clinically outside appropriately regulated research trials. 2026 systematic review of human BPC-157 evidence.

The US Food and Drug Administration has also identified potential safety concerns involving immunogenicity, peptide-related impurities and active pharmaceutical ingredient characterisation in compounded BPC-157 products. These concerns reinforce the importance of verified formulation and quality documentation. FDA – Safety considerations for BPC-157.

Quality, documentation and transparency

Product documentation is particularly important for peptide presentations involving delivery devices.

Relevant information should include:

• Confirmed peptide identity.

• Verified total quantity.

• Manufacturer identification.

• Batch or lot identification.

• Batch-specific Certificate of Analysis, if available.

• Analytical identity and purity results, where documented.

• Pen manufacturer and device specifications.

• Product-specific storage and handling information.

• Packaging and component information.

No independent testing results, purity percentage, GMP certification or batch-specific analytical documentation have been supplied for this listing.

These characteristics should not be assumed from the brand name or product presentation.

UK regulatory information

BPC-157 does not have an established MHRA marketing authorisation as a medicine.

The MHRA’s guidance explains that medicines without the required UK marketing authorisation cannot be advertised as licensed medicines. The classification of a product depends on its presentation and intended purpose, not simply the wording printed on its label.

For further information, consult the official MHRA guidance on advertising medicines and GOV.UK guidance on unlicensed medicinal products.

A research-use disclaimer does not automatically make a product or its supply lawful for every purpose.

Important product notice

BPC-157 10mg Pen is described here for scientific identification and research-literature reference. The supplied pen’s composition, device specifications and regulatory classification have not been independently verified.